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ABSTRACT 
 
Aims: Certain personality features and psychiatric symptoms are often observed in 
Parkinson’s Disease (PD) but the effects of deep brain stimulation (DBS) of the 
subthalamic nucleus (STN) on psychiatric aspects of PD remain largely unclear. We 
aimed to evaluate changes in personality and psychiatric symptoms before and after 
STN-DBS in patients affected by PD. Moreover, motor symptoms and L-dopa equivalent 
daily dose (LEDD) were also investigated.  
Methodology: Eighteen PD patients consecutively admitted at the San Giovanni Battista 
Hospital of the University of Turin to undergo STN-DBS were recruited. Participants were 
neurologically assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS), 
and the Hoehn and Yahr scale. They were also psychiatrically evaluated with both      
self-report and clinician-rated instruments: Temperament and Character Inventory    
(TCI), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory – Y form (STAI-Y), 
Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-
A). 
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Results: After STN-DBS, temperament dimensions of the TCI significantly changed 
whilst character did not. Moreover, both HAM-D and HAM-A improved but BDI and STAI-
Y resulted unmodified. We found significant improvements as regards the UPDRS part II 
and part III scales and L-dopa equivalent daily dose.  
Conclusions: The change we found on biological dimensions of temperament after 
STN-DBS raises the intriguing hypothesis that surgery may entail subtle modifications of 
personality in PD patients. Further studies are needed to confirm these findings. 
 
 
Keywords: Parkinson's disease; deep brain stimulation; subthalamic nucleus; personality; 
reward dependence; temperament. 
 
1. INTRODUCTION 
 
Psychiatric symptoms frequently occur in Parkinson’s Disease (PD) and have important 
consequences on patients’ quality of life and daily functioning. Psychiatric symptomatology 
includes depression (30-40%), anxiety (40%) [1], psychosis (20-50%) [2], and sleep 
disturbances (88%) [3]. Still, these data might be underestimated inasmuch PD patients 
often do not mention their non-motor symptoms [4]. 
 
Since the late 1990s, deep brain stimulation (DBS) of the subthalamic nucleus (STN) has 
become a well-established procedure for advanced PD patients to greatly improve motor 
symptoms and quality of life [5]. Moreover, notwithstanding the variable risk of adverse 
events (e.g. surgical site infection, dystonia, gait disturbance), this procedure was found to 
be more effective than medical management alone [6,7]. Still, STN-DBS has the advantage 
to reduce L-dopa equivalent daily dose (LEDD; i.e., a useful summary of the total daily 
antiparkinsonian medication a patient is receiving independently of treatment regimen) [8] 
possibly limiting its unwanted motor [2] and psychiatric [9] side-effects on the medium and 
long-run. 
 
The effects of STN-DBS on psychiatric outcome in PD patients remain largely unclear also 
because of a lack of systematic psychiatric screening [10]. The majority of psychiatric 
symptoms that occur after surgery are frequently transient and manageable and vary from 
depression to hypomania [10]. However, this procedure reported encouraging outcomes as 
regards psychiatric symptomatology [8,11,12].  
 
The motor function of the STN has been well documented [13] but those mechanisms 
underlying psychiatric symptoms are poorly understood [14] raising the hypothesis of a 
multifactorial etiology which is thought to include preoperative PD-related aspects, 
dopaminergic medications, surgical factors, and psychosocial effects [15]. However, basal 
ganglia and STN represent the substrate not only for complex motor cortico-subcortical 
loops but also for limbic connections processing thoughts, emotions, and behaviour [11,14] 
with animal and human studies on PD [16,17] providing intriguing evidence for the role of the 
STN in these regards. 
 
With respect to personality, a general consensus does not exist as to whether personality 
features like punctuality, introversion, moral rigidity, and conventionality might be considered 
as premorbid traits and eventually risk factors of PD [18-20]. These traits are underpinned by 
both dopaminergic and GABAergic systems [21]; in particular, novelty seeking (NS) is a 
personality dimension thought to mirror the dopamine function in the brain [22] and it has 
been often found to be low in PD individuals [23-25].  
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The available body of literature regarding personality changes in PD individuals who 
underwent STN-DBS is even scarcer and only two studies [26,27] investigated these 
aspects. The study conducted by Houeto and Coworkers [26] with the Temperament and 
Character Inventory-Revised (TCI-R) [28] did not find significant changes in patients’ 
personality traits after surgery. In our previous work, using the Temperament and Character 
Inventory (TCI) [22], we found that two NS subscales were significantly higher in PD patients 
who underwent the STN-DBS intervention [27].  
 
The primary aim of this study was to investigate changes in personality and psychiatric 
symptoms - using self-administered and clinician-rated instruments - in PD individuals 
treated with STN-DBS, and the secondary aim was to measure also motor symptoms. Both 
changes in NS scores as well as motor improvement were expected.  
 
2. METHODOLOGY  
 
2.1 Patients 
 
We consecutively enrolled 18 participants affected by PD, according to the UKPD-Brain-
Bank criteria [29]. All participants, N=16 (88.9%) males and N=2 (11.1%) females were 
recruited at the San Giovanni Battista Hospital of the University of Turin, Italy, between 
September, 1st 2010 and  January, 31st 2012. Mean age at intervention was 61.22±6.69 
years and at follow-up was 62.47±5.6 years; mean duration of illness was 15.44±4 years.  
 
Exclusion criteria were: a) age > 70 years old; b) severe medical comorbidity (e.g., epilepsy 
or diabetes); c) severe Axis I psychiatric comorbidity; d) drug dependence; e) cognitive 
impairment (Mini-Mental state examination <27/30 [30]). Patients were all Caucasian. 
 
2.2 Surgical Procedure 
 
Deep brain stimulation (DBS) is a neurosurgical procedure consisting in placing a brain 
pacemaker which sends electrical impulses through implanted electrodes to specific parts of 
the brain to deliver continuous high-frequency electrical stimulation for the treatment of 
movement and affective disorders. Electrodes are placed deep in the brain and are linked to 
a stimulator/battery device. The electrodes are placed on both the left and right sides of the 
brain through small holes made at the top of the skull. A neurostimulator, similarly to a heart 
pacemaker, uses electric pulses to help regulate brain activity. When turned on, the 
stimulator sends electrical pulses to modify nerve signals involved in tremors, rigidity, and 
other symptoms. DBS can be performed on both sides of the brain or in a combination of 
targets depending on the symptoms to treat and may include thalamus, globus pallidus, or 
the subthalamic nucleus. The latter is the target we used in previous [27] and current 
research. A deep brain stimulator system has three parts that are implanted inside the body: 
A) Lead – a thin, insulated wire with a number of electrodes at the tip that deliver electric 
pulses to the brain tissue. It is inserted through a small opening in the skull; the tip of the 
electrode is positioned within the targeted brain area. B) Extension – an insulated wire that is 
passed under the skin of the head, neck, and shoulder and connects the lead to the 
neurostimulator. C) Neurostimulator– a programmable battery-powered pacemaker device 
that creates electric pulses. It is placed under the skin of the chest below the collarbone or in 
the abdomen. 
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All procedures involving experiments on human subjects were done in accord with the 
ethical standards of the Committee on Human Experimentation of the institution in which the 
experiments were done or in accord with the Helsinki Declaration of 1975. All participants 
provided written informed consent according to the Ethical Committee of the Department of 
Neuroscience of the University of Turin. 
 
2.3 Neurological Assessment 
 
All participants were clinically assessed one month before (T0) and 6 months after (T1) the 
STN-DBS intervention by a neurologist using the Unified Parkinson’s Disease Rating Scale 
(UPDRS) [31] parts II and III, and the Hoehn and Yahr scale [32]. 
 
2.3.1 Unified Parkinson’s disease rating scale (UPDRS) 
 
The UPDRS [31] is a scale that was developed to provide a comprehensive and flexible 
means to monitor PD-related disability. The scale has four components: part I: mentation, 
behavior and mood; part II: activities of daily living; part III: motor; and part IV: complications. 
According to the aims of this study, in order to assess motor functioning only parts II and III 
of this scale were included in subsequent analysis. 
 
2.3.2 Hoehn and Yahr scale 
 
The Hoehn and Yahr scale [32] is a commonly used system for describing how the 
symptoms of PD progress with a range of five stages: 1. unilateral involvement only usually 
with minimal or no functional disability; 2. bilateral or midline involvement without impairment 
of balance; 3. bilateral disease: mild to moderate disability with impaired postural reflexes, 
physically independent; 4. severely disabling disease; still able to walk or stand unassisted; 
5. confinement to bed or wheelchair unless aided.  
 
2.4 Psychiatric Assessment 
 
After the neurological assessment, all participants were clinically assessed by an 
experienced psychiatrist one month before (T0) and 6 months after (T1) the STN-DBS 
intervention using both self-report instruments and semi-structured interviews as follows:  
 
2.4.1 Temperament and character inventory (TCI) 
 
The TCI [22] is divided into seven dimensions. Four of these assess temperament (novelty 
seeking [NS], harm avoidance [HA], reward dependence [RD], and persistence [P]), defined 
as partly heritable emotional responses, stable throughout life, mediated by 
neurotransmitters in the central nervous system. The other three dimensions assess 
character (self-directedness [SD], cooperativeness [C], and self-transcendence [ST]) which 
is influenced by both genetic factors and social learning. The TCI showed good properties as 
regards internal consistency and test-retest reliability [33]. 
 
2.4.2 Beck depression inventory (BDI) 
 
The BDI [34] is a self-administered questionnaire used to assess the severity of depressive 
symptoms and demonstrated good psychometrics [35]. 
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2.4.3 State-trait anxiety inventory – Y Form (STAI – Y) 
 
The STAI-Y [36] is a brief self-report assessment designed to measure and differentiate 
between anxiety as a trait and a state with good psychometric properties [37]. 
 
2.4.4 Hamilton depression rating scale (HAM-D) 
 
The HAM-D [38] rates the severity of symptoms observed in depression such as low mood, 
insomnia, agitation, anxiety, and weight loss. Clinicians have to rate each question by 
interviewing the patient and by observing patient's symptoms. The HAM-D showed good 
inter-rater and test-retest reliability [39]. 
 
Although HAM-D scores were moderately high, when clinically interviewed all patients 
reported negative anamnesis for mood disorders; only four patients affected by minor 
depression resulted to be included in this sample.  
 
2.4.5 Hamilton anxiety rating scale (HAM-A) 
 
The HAM-A [40] is a 14-item questionnaire that covers anxiety symptomatology. The test is 
administered by clinicians who rates patients’ answers and the questions are split into seven 
for psychic anxiety and seven for somatic anxiety. Cronbach’s alpha for the HAM-A was .89 
[41] and its test-retest reliability was good [42].  
 
2.5 Statistical Analysis 
 
The Statistical Package for Social Sciences, version 17.0 (SPSS, IBM, Armonk, NY) 
statistical software package was used for data analysis. All scores of psychometric tests 
before and after the intervention have been compared with the paired sample t-test.  
 
Potential correlations between LEDD and personality changes have been studied running 
bivariate (Pearson) linear correlations between changes in personality (i.e., NS at T0 – NS at 
T1 = ∆NS), psychiatric symptomatology, and LEDD (i.e., LEDD at T0 – LEDD at T1 = 
∆LEDD). 
 
An alpha level <.05 was considered statistically significant.  
 
3. RESULTS  
 
3.1 STN-DBS and PD Symptomatology 
 
With this study we aimed at assessing changes in PD symptomatology after STN-DBT.  
 
The Hoehn and Yahr scale has been used to describe PD staging before intervention in the 
off-medication condition. Participants were classified as follows: N=2 (11%) stage II, N=4 
(22%) stage III, N=6 (33.5%) stage IV and N=6 (33.5%) stage V. 
The UPDRS part II changed significantly from 23.86±6.52 to 10.02±7.93 (P<.001) as well as 
part III from 51.69±12.05 to 24.58±8.73 (P<.001, Table 1). 
 
LEDD, expressed in milligrams (mg) significantly changed before and after the intervention 
(Table 1). We showed no correlations between the LEDD difference before and after STN-
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DBS (∆LEDD) and changes in personality, anxiety and depression scores (∆LEDD vs ∆NS 
r=.06, P=.79; ∆LEDD vs ∆HA r=.14, P=.55; ∆LEDD vs ∆RD r=.32, P=.18; ∆LEDD vs ∆HAM-
D r= -.18, P=.46; ∆LEDD vs ∆HAM-A r= -.12, P=.61). 
 
In synthesis, UPDRS parts II and III as well as LEDD changed significantly after STN-DBS.  
  
Table 1. L-dopa equivalent daily dose (LEDD) and Unified Parkinson’s disease rating 
scale (UPDRS) part II and III before (T0) and after (T1) deep brain stimulation of the 
subthalamic nucleus (STN-DBS) 
 
 Mean±SD   
 T0 T1 t P 
LEDD (mg) 1169.86±435.71 527.5±283.99 8.76 .001 
UPDRS II 23.86±6.52 10.02±7.93 5.64 .001 
UPDRS III 51.69±12.05 24.58±8.73 8.76 .001 
Legend: LEDD: L-dopa equivalent daily dose (expressed in milligrams, mg) 
UPDRS II: Unified Parkinson’s Disease Rating Scale, part II 
UPDRS III: Unified Parkinson’s Disease Rating Scale, part III 
 
3.2 STN-DBS and Personality and Psychiatric Symptoms 
 
With this study we aimed at assessing changes in personality and psychiatric symptoms 
after STN-DBT. We found significant differences on the TCI; in particular, as regards 
temperament dimensions, novelty seeking (NS, P=.02) and reward dependence (RD, 
P<.001) scores resulted to be higher whilst harm avoidance (HA, P=.04) was found to be 
lower after STN-DBS (Table 2). On the other hand, we did not find any difference on TCI 
character domains before and after STN-DBS (Table 2). 
 
No significant differences were reported either on BDI or STAI-Y scores (data not shown) 
whereas both HAM-D and HAM-A scales significantly improved before and after STN-DBS 
(HAM-D: T0 16.28±8.50 [4 patients resulted to be affected by clinically relevant minor 
depression] T1 11.94±6.42, P<.001; HAM-A: T0 13.39±5.64 T1 10.50±5.07, P<.001). 
 
In closing, temperament dimensions as well as interviewer-based assessments of anxiety 
and depression improved significantly after the intervention.  
 
Table 2. Temperament and character domains of the Temperament and Character 
Inventory (TCI) before (T0) and after (T1) deep brain stimulation of the subthalamic 
nucleus (STN-DBS) 
 
 Mean±SD   
 T0 T1 t P 
Novelty seeking (NS) 14.78±5.79 18.06±8.01 -2.49 .02 
Harm avoidance (HA) 19.28±6.25 16.39±5.21 2.20 .04 
Reward dependence (RD) 13.83±3.20 15.28±2.88 -4.57 .001 
Persistence (P) 4.72± 1.44 5.17±1.46 -1.28 .21 
Self-directedness (SD) 30.44±4.89 30.06±6.62 0.28 .73 
Cooperativeness (C) 31.11±4.73 32.61±4.47 -1.74 .01 
Self-transcendence (ST) 15.61±4.75 14.11±5.29 1.46 .16 
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4. DISCUSSION 
 
The primary aim of this study was to investigate changes in personality traits in individuals 
affected by PD assessed one month before and six months after STN-DBS. Our main finding 
is that temperament dimensions changed after surgery, differently from character ones that 
remained stable. It is noteworthy that not only NS but also HA and RD changed after 
surgery. Temperament has been theoretically [22] and experimentally [43,44] shown to 
mirror the biological networks in the brain and RD has been shown to reflect the attitude of 
an individual to react to reinforcements and maintain a certain behavior previously 
associated to social reward or punishment [22]. All in all, this study raises the possibility that 
the aforementioned changes may be due to STN-DBS and its effects on those brain 
networks mostly related to motivational aspects.  
 
NS increased and it has been found to have a major role in PD since dopamine-related [22] 
and low scores on this subscale in PD patients have been consistently found in literature 
[23-25]. Broadly speaking, this feature characterizes individuals who are rigid, frugal, stoic, 
and persistent [27], showing startling similarities with individuals affected by Obsessive-
Compulsive Disorder (OCD). Moreover, the STN is a shared target of DBS for both 
diagnoses [45]; in fact, a double-blind multicenter study conducted on refractory OCD 
individuals demonstrated the effectiveness of STN-DBS in significantly lowering obsessive-
compulsive symptomatology [46]. Accordingly, also in parkinsonian patients [5,47] the 
stimulation of the STN strongly improved their OCD traits further suggesting a role of the 
STN in the integration of associative-cognitive, limbic-emotional, and sensorimotor inputs 
[48]. Therefore, PD and OCD patients may have a partially shared neurobiological 
substratum that could be measured by this temperament dimension.  
 
HA represents a complex temperament trait that has been found to be linked to the 
neurotransmitter serotonin in the brain [22], playing indeed a potentially relevant role in the 
development of anxiety and depression. Since HA changes have been found to correlate 
with depressive scores [49] our results are in line with previous literature [26,50] and with the 
improvement we reported on the clinician-rated assessments of anxiety and depression.    
 
In order to better understand the significant change in RD that PD patients showed after 
surgery, the complexity of the STN should be taken into account. This nucleus is thought to 
be part of a more distributed cortico-subcortical network involved in the selection, facilitation 
and inhibition of movements, emotions, and behaviors [50]. The STN can be divided into 
functionally segregated areas: motor, oculomotor, associative, and limbicand it is involved in 
decision-making processes [11]. Although the role of STN in the motor cortico-basal ganglia-
thalamo-cortical loop has been widely described, its role on limbic functions remains unclear 
[14]. The medial tip of the STN represents its limbic portion receiving inputs from the anterior 
cingulate cortex, the medial prefrontal cortex, the limbic part of the striatum (nucleus 
accumbens), the ventral tegmental area, and the limbic ventral pallidum. The limbic portion 
of the STN sends projections to the limbic sections of substantia nigra and the ventral 
tegmental area. This circuit could be involved in linking the STN to the mesolimbic 
dopaminergic network and to limbic cortical structures, potentially explaining limbic 
impairments (e.g. apathy and depression) possibly observed after DBS [10,15]. Moreover, 
research on human [16] and animal models [17,51] suggested the STN as involved in 
reward and motivational functions. The change on RD we found raises the intriguing 
possibility of a surgery-related change in these networks but larger studies with control 
groups may want to replicate this finding.  
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Given the dearth of systematic psychiatric evaluations of PD patients presenting to STN-
DBS, we aimed also at assessing depression and anxiety symptomatology before and after 
surgery with both self-report and clinician-rated instruments. In line with previous literature 
[12,50,52] we found encouraging results although we reported mixed findings using objective 
and subjective assessment tools with significant improvement only on the clinician-rated 
evaluations. Since many psychosocial factors may be taken into account in self-administered 
reports of anxiety and depression levels, our study is in line with previous literature 
questioning the reliability of patient-rated assessments [10] potentially generating mixed 
findings [1].  
 
It is of interest that the changes on TCI, HAM-A and HAM-D were not linearly correlated with 
LEDD modifications since chronic replacement medication has been called into question in 
the development and worsening of psychiatric symptoms [9,53].  
 
Our data are only partially in line with previous literature. In fact, our group previously 
reported [27] higher scores on some NS sub-dimensions after STN-DBS; however, it should 
be borne in mind that the design of our earlier study was profoundly different from the 
current one. In fact, a longitudinal approach had not been undertaken in our previous work 
and a different sample composition had been considered. Hence, the results may be not fully 
comparable. Moreover, Houeto and Cowokers [26] did not find any change in personality 
before and after surgery. This difference could be better understood with the following 
considerations: 1) two different instruments were used (TCI versus TCI-R); 2) they excluded 
personality disorders on the basis of a different a priori hypothesis; and 3) sampling biases 
may account for the lack of significance of NS scores.   
 
As a secondary aim, we investigated motor symptoms after STN-DBS and as expected our 
positive results are in line with previous literature [5-7,54]. 
 
5. CONCLUSION 
 
In closing, STN-DBS resulted to be effective in PD on one hand as regards those 
temperament traits mostly related to limbic and reward circuits and on the other hand in 
improving anxious and depressive symptomatology with no correlations with replacement 
therapy. Improvement of motor function after this intervention was also confirmed. However, 
the present findings should be taken with caution since our work suffers from small sample 
size, lack of control group, and relatively short follow-up. Finally, notwithstanding an accurate 
psychiatric evaluation at baseline, four patients affected by clinically relevant minor 
depression were included. Future studies are indeed warranted to confirm our findings. 
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